Physician profile
Marci Michelle Manna
NPI 1265545297
$352.97
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.14 · 2021: $250 · 2022: $82.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97.16 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $63.07 | 2020-2022 | |
| Alkermes, INC. | $62.70 | 2021 | |
| Indivior INC. | $45.54 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.36 | 2021 | |
| Sunovion Pharmaceuticals INC. | $24.26 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.21 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.67 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marci Manna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.